Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
PR Newswire•21/10/2026•08:02 ET
1
Key Highlights
- ➤Nu-3 rapidly eradicated tested resistant pathogens within minutes in vitro
- ➤Nu-3 showed slight MIC increases versus 600- to 2,000-fold for ciprofloxacin
- ➤Phase 2a trial in mildly infected diabetic foot ulcers is underway
- ➤Topline Phase 2a data expected in the first quarter of 2027
Expert Statements
Kelvin Cooper, Chief Executive Officer and Senior Vice President of Research and Development at Lakewood-Amedex Biotherapeutics
“The data being presented at IDWeek reinforce the potential of Nu-3 to play an important role in addressing the growing threat of antimicrobial resistance”
Kelvin Cooper, Chief Executive Officer and Senior Vice President of Research and Development at Lakewood-Amedex Biotherapeutics
“Nu-3's broad-spectrum and rapid bactericidal activity, combined with its low potential for resistance development, underscore its potential as a differentiated antimicrobial therapy for iDFUs. With our Phase 2a trial now underway, we look forward to building on these encouraging findings as we advance Nu-3 toward our goal of providing a potential new, topically delivered treatment option for patients with difficult-to-treat infections.”
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026 PR Newswire
Research highlights Nu-3's rapid bactericidal activity against clinically relevant resistant pathogens and its potential as a topical treatment for infected diabetic foot ulcers
Get started
Create a free account to read the full story.